Loading…
aTyr Pharma, Inc. is projected to rise to $0.6131 by 2027, a +28% move from its current price of $0.4782. ATYR is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $0.4357 | $0.4787 | $0.526 | +0.10% |
| May 30 | $0.4194 | $0.4792 | $0.5474 | +0.20% |
| May 31 | $0.4075 | $0.4797 | $0.5646 | +0.31% |
| Jun 1 | $0.3977 | $0.4802 | $0.5797 | +0.41% |
| Jun 2 | $0.3894 | $0.4806 | $0.5933 | +0.51% |
| Jun 3 | $0.382 | $0.4811 | $0.606 | +0.62% |
| Jun 4 | $0.3754 | $0.4816 | $0.6179 | +0.72% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.3754 | $0.4816 | $0.6179 | +0.72% |
| Week 2 | $0.341 | $0.4851 | $0.69 | +1.44% |
| Week 3 | $0.3173 | $0.4886 | $0.7522 | +2.17% |
| Week 4 | $0.299 | $0.4921 | $0.8099 | +2.90% |
| Week 5 | $0.2839 | $0.4956 | $0.8651 | +3.64% |
| Week 6 | $0.2712 | $0.4992 | $0.9189 | +4.39% |
| Week 7 | $0.2601 | $0.5028 | $0.9719 | +5.14% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
ATYR Pharma, Inc. is a clinical stage biotechnology company that engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States.
Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2, is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; a Phase 2 clinical trial treats Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs), and it is pursuing treatment of other ILDs such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, in preclinical development for fibrosis, and ATYR0750, a domain of alanyl-tRNA synthetase for liver disorders.
aTyr Pharma, Inc. has a collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
ATYR is the asset ATYR Pharma, Inc., trading in the healthcare sector. It currently has a price of $0.49 and a market cap of $48.05M with a market rank of 4,613.
The stock carries a bearish technical backdrop in the near term, but the longer‑term forecast presents a bullish trajectory with meaningful upside potential through 2050. Current price and fundamentals sit within a framework of evolving clinical programs and collaborations.
A major floor 17.2% below — a decisive break under it would weaken the trend.
The nearest floor, 17.2% below — buyers have tended to step in here.
The nearest ceiling, 117.5% above — a clean break opens room to run.
A major ceiling 168.1% above — clearing it would confirm fresh momentum.
Key ATYR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ATYR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.5024 | Sell | $0.4975 | Sell |
| MA 10 | $0.4975 | Sell | $0.5414 | Sell |
| MA 20 | $0.6727 | Sell | $0.6214 | Sell |
| MA 50 | $0.7564 | Sell | $0.7293 | Sell |
| MA 100 | $0.8052 | Sell | $0.8951 | Sell |
| MA 200 | $1.36 | Sell | $1.39 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 36.93 | Neutral |
| Stoch RSI (14) | 29.48 | Neutral |
| CCI (20) | -68.51 | Neutral |
| Williams %R (14) | -85.20 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | -49.47 | Sell |
| Bollinger %B (20,2) | 0.26 | Neutral |
| Stochastic %K (14) | 14.80 | Buy |
| TRIX (15) | -1.35 | Sell |
| Awesome (5,34) | -0.23 | Sell |
| Ultimate (7,14,28) | 36.04 | Neutral |
| Momentum (10) | -0.05 | Sell |
| Aroon Osc (25) | -20.00 | Sell |
| Hull MA (9) | 0.49 | Sell |
| ADX (14) | 20.28 | Sell |
| ATR (14) | 0.05 | Info |
The 30-day technical picture shows bearish sentiment overall. RSI14 stands at 40, with the 50‑day simple moving average at $0.772 and the 200‑day simple moving average at $1.40.
Key support sits at $0.396 and resistance at $1.04. The 30‑day range runs from $0.2533 to $0.9479, illustrating a broad fluctuation band near the current price.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.396 | $0.4782 | $0.6741 | 0% | Neutral | |
| $0.4412 | $0.6131 | $0.9218 | +28% | Bullish | |
| $0.5626 | $0.8297 | $1.33 | +74% | Bullish | |
| $0.6178 | $0.959 | $1.61 | +101% | Bullish | |
| $0.5945 | $0.967 | $1.69 | +102% | Bullish | |
| $0.6086 | $1.03 | $1.87 | +116% | Bullish | |
| $0.5318 | $0.9424 | $1.75 | +97% | Bullish | |
| $0.5391 | $0.9947 | $1.90 | +108% | Bullish | |
| $0.8179 | $1.57 | $3.07 | +228% | Bullish | |
| $0.8563 | $1.71 | $3.42 | +257% | Bullish | |
| $1.12 | $2.48 | $5.46 | +419% | Bullish | |
| $1.64 | $3.65 | $8.40 | +664% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.396 | $0.4782 | $0.5702 | +0.00% |
| June 2026 | $0.4302 | $0.5159 | $0.6411 | +7.89% |
| July 2026 | $0.4304 | $0.5249 | $0.669 | +1.74% |
| August 2026 | $0.3935 | $0.4864 | $0.632 | -7.34% |
| September 2026 | $0.389 | $0.4861 | $0.6415 | -0.06% |
| October 2026 | $0.4119 | $0.52 | $0.6959 | +6.97% |
| November 2026 | $0.4008 | $0.5106 | $0.6916 | -1.81% |
| December 2026 | $0.3828 | $0.492 | $0.6741 | -3.64% |
Click any year to see its month-by-month ATYR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, ATYR is projected to trade between $0.396 and $0.6741, averaging $0.4782 — a potential gain of 0% from today's $0.4782. A consolidation phase looks the most probable path here.
aTyr Pharma, Inc.'s 2027 outlook centres on $0.6131, within a $0.4412 to $0.9218 range. That is up +28% on the projected 2026 average. That marks a +28% change versus current levels. Momentum favours further upside here.
By 2028, ATYR could reach as high as $1.33, with a base case around $0.8297 and support toward $0.5626 — roughly +74% from $0.4782. Buyers look set to stay in control over this stretch.
Expect ATYR to range from $0.6178 to $1.61 through 2029. The $0.959 average target implies a +101% move from current prices. That is up +16% on the projected 2028 average. Momentum favours further upside here.
The ATYR price prediction for 2030 points to an average of $0.967 (low $0.5945, high $1.69) — a potential gain of +102% on today's $0.4782. Buyers look set to stay in control over this stretch.
In 2031, ATYR is projected to trade between $0.6086 and $1.87, averaging $1.03 — a potential gain of +116% from today's $0.4782. That is up +7% on the projected 2030 average. Momentum favours further upside here.
aTyr Pharma, Inc.'s 2032 outlook centres on $0.9424, within a $0.5318 to $1.75 range. That is -9% versus the projected 2031 average. That marks a +97% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, ATYR could reach as high as $1.90, with a base case around $0.9947 and support toward $0.5391 — roughly +108% from $0.4782. Momentum favours further upside here.
Expect ATYR to range from $0.8179 to $3.07 through 2034. The $1.57 average target implies a +228% move from current prices. That is up +58% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The ATYR price prediction for 2035 points to an average of $1.71 (low $0.8563, high $3.42) — a potential gain of +257% on today's $0.4782. Momentum favours further upside here.
In 2040, ATYR is projected to trade between $1.12 and $5.46, averaging $2.48 — a potential gain of +419% from today's $0.4782. That is up +45% on the projected 2035 average. Buyers look set to stay in control over this stretch.
aTyr Pharma, Inc.'s 2050 outlook centres on $3.65, within a $1.64 to $8.40 range. That is up +47% on the projected 2040 average. That marks a +664% change versus current levels. Momentum favours further upside here.
Investing $1,000 in ATYR today (≈ 2,091.17524 ATYR) could be worth
$7,641.81
+$6,641.81 (+664%) by 2050 · US Dollar
Based on the average projected ATYR price of $3.65 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ATYRwould be worth at today's price.
$1,000 invested in ATYR on May 27, 2025 (≈ 258.39794 ATYR) would be worth
$123.57
-$876.43 (-87.6%) today · 0.12× · US Dollar
Based on a ATYR entry price of $3.87 vs. today's $0.4782.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.531 | $900.56 | -9.9% |
| 1 month ago | $0.791 | $604.55 | -39.5% |
| 3 months ago | $0.99 | $483.03 | -51.7% |
| 6 months ago | $0.781 | $612.29 | -38.8% |
| 1 year ago | $3.87 | $123.57 | -87.6% |
| All time (5.0y) ago | $4.62 | $103.51 | -89.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ATYR forecast.
Our base-case forecast reaches $0.96 around 2030.
Implied market cap at $0.96: $94.13M
The multi‑year forecast remains bullish from 2027 onward, with a rising average price and expanding upside. In 2027 the average is $0.6404 with a 30.7% ROI and bullish sentiment, rising further in 2028 to an average of $0.8425 (72% ROI) and 2029 to $0.9873 (101.5% ROI). By 2030 the average is $1.01 with a 105.4% ROI and bullish sentiment, and by 2031 the average reaches $1.05 with a 114% ROI.
The trajectory continues to 2034 where the average is $1.61 (228.6% ROI) and 2035 where the average is $1.77 (260.7% ROI).
Looking further, 2040 shows an average of $2.54 with a 418.6% ROI, and 2050 projects an average of $3.80 with a 674.8% ROI, under bullish sentiment across these endpoints. The forecasted path is accompanied by high volatility, noted as 200% annualized volatility, underscoring the downside risk and uncertainty inherent in these projections.
Tap a question to reveal the answer.
In 2030, the forecast shows an average price of $1.01 with a min of $0.6185 and a max of $1.76, and an ROI of 105.4%, with bullish sentiment.
Forecasts show bullish sentiment from 2027 onward with rising averages and ROIs, including 30.7% in 2027 and 105.4% in 2030, rising to 674.8% by 2050, though these are estimates and carry inherent uncertainty.
Yes. The forecast shows a max of $3.15 in 2034 and $3.54 in 2035, with a 2040 max of $5.59.
Market cap $48.05M; rank 4613.
aTyr Pharma, Inc. Community Discussion
0Share your aTyr Pharma, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.